YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
1 other identifier
interventional
N/A
10 countries
53
Brief Summary
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
53 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 4, 2002
CompletedFirst Posted
Study publicly available on registry
November 6, 2002
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2004
CompletedJune 7, 2012
June 1, 2012
November 4, 2002
June 6, 2012
Conditions
Keywords
Interventions
Sponsors & Collaborators
- Astellas Pharma Inclead
- Astellas Pharma US, Inc.collaborator
Study Sites (53)
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
San Bernardino Urological Associates
San Bernardino, California, United States
Western Clinical Research, Inc.
Torrance, California, United States
Shands Hospital
Gainesville, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Georgia Urology,PA Research Institute
Atlanta, Georgia, United States
University of Chicago, Section of Hematology/Oncology
Chicago, Illinois, United States
University of Illinois, Department of Urology
Chicago, Illinois, United States
Michiana Hematology/Oncology
South Bend, Indiana, United States
The Urologic Institute of New Orleans
Gretna, Louisiana, United States
Henry Ford Hospital
Detroit, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
Memphis Cancer Center
Memphis, Tennessee, United States
Virginia Mason Medical Center
Seattle, Washington, United States
Department of Medical Oncology, The Canberra Hospital
Canberra, Australia
Department of Medical Oncology, Concord Hospital Medical Centre
Concord, Australia
Division of Oncology Ward, Royal Brisbane Hospital
Herston, Australia
Department of Clinical Oncology, Royal North Shore Hospital
St Leonards, Australia
Cancer Care Centre, St. George Hospital
Sydney, Australia
Department of Medical Oncology, Newcastle Mater Hospital
Waratah, Australia
Southern Medical Day Care Centre
Wollongong, Australia
Queen Elizabeth Hospital, Clinical Hematology & Oncology
Woodville, Australia
Cliniques Universitaires St-Luc, Service d'Urologie
Brussels, Belgium
Centre Hospitalier Notre Dame et Reine Fabiola, Service d'oncologie
Charleroi, Belgium
Centre Paul Papin
Angers, France
Service d'Urologie, Hôpital Henri Mondor
Créteil, France
Pavillon V, Service d'Urologie et de transplatation, Hôpital Edouard Herriot
Lyon, France
Service d' Urologie CHU, Hopital Bichat
Paris, France
Krankenhause am Urban, Urologie Dieffenfachstr
Berlin, Germany
Dept Urology University of Essen
Essen, Germany
Urologische Klinik der MHH
Hanover, Germany
Klinikum Mannheim Urology
Mannheim, Germany
Mater Misericordiae Hospital
Dublin, Ireland
Universitair Medisch Centrum Utrecht, Dienst Medische Oncologie
Utrecht, Netherlands
Kilinika Chemioterapii, Centrum Onkologii Instytut im M sklodowskiej Curie
Krakow, Poland
Oddzial Chemioterapii
Krakow, Poland
Klinika Chemioterapii AM
Lodz, Poland
Samodzielny Publiczny Zaklad Opieki zdrowotnej, Wojewodzki Osrodek Onkologii
Opole, Poland
Szpital Wojewodzki im Sw Lukasza SP ZOZ Tarnow
Tarnów, Poland
Klinika Nowotworow Ukladu
Warsaw, Poland
Szpital CSK WAMl, Klinika Okologii
Warsaw, Poland
Hospital Clinic i Provincial, Servicio de Oncologia
Barcelona, Spain
Hospital General Vall d'Hebron, Servicio de Oncología
Barcelona, Spain
Hospital Universitario de Getafe, Servicio de Urologia, Crta
Getafe (Madrid), Spain
Hospital Universitario Príncipe de Asturias, Servicio de Urología
Madrid, Spain
Instituto Valenciano de Oncologia, Servicio de Oncologia
Valencia, Spain
Department of Urological Research, Derriford Hospital
Devon, United Kingdom
Clinical Research Centre, St George's Hospital, Urology Division
London, United Kingdom
Department of Urology, St Bartholomew's Hospital
London, United Kingdom
Imperial College School of Medicine, Dept Cancer Medicine
London, United Kingdom
Department of Urology, East Surrey Hospital
Surrey, United Kingdom
Royal Surrey County Hospital
Surrey, United Kingdom
St Richard's Hospital
West Sussex, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 4, 2002
First Posted
November 6, 2002
Study Completion
June 1, 2004
Last Updated
June 7, 2012
Record last verified: 2012-06